Showing results (101-110 of 115) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801Kunihiro Tsukasaki, Atae Utsunomiya, Haruhiko Fukuda, et al.Cancer Science|November 21, 2008
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphomaKensei Tobinai, Takashi Watanabe, Michinori Ogura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211Motoko Yamaguchi, Kensei Tobinai, Masahiko Oguchi, et al.International Journal of Hematology|March 10, 2004
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301Takeaki Takenaka, Kuniaki Itoh, Takayo Suzuki, et al.International Journal of Hematology|November 16, 2010
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)Michinori Ogura, Kuniaki Itoh, Tomohiro Kinoshita, et al.British Journal of Haematology|June 17, 2014
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)Takuya Fukushima, Shogo Nomura, Masanori Shimoyama, et al.International Journal of Hematology|March 4, 2010
Prognostic analysis and a new risk model for Hodgkin lymphoma in JapanKuniaki Itoh, Tomohiro Kinoshita, Takashi Watanabe, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.Blood|March 9, 2006
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in JapanSung-Won Kim, Tetsuya E Tanimoto, Noriyuki Hirabayashi, et al.Japanese Journal of Clinical Oncology|September 2, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphomaKen Ohmachi, Tomohiro Kinoshita, Dai Maruyama, et al.Pageof 12